B. Zweifel

发表

A Novel Autotaxin Inhibitor Reduces Lysophosphatidic Acid Levels in Plasma and the Site of Inflammation

J. Gierse, J. Masferrer, A. Wittwer, 2010, Journal of Pharmacology and Experimental Therapeutics.

Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation.

Daniel P. Walker, J. Masferrer, Y. M. Fobian, 2013, Bioorganic & medicinal chemistry letters.

Pharmacology of PF-4191834, a Novel, Selective Non-Redox 5-Lipoxygenase Inhibitor Effective in Inflammation and Pain

J. Masferrer, M. Graneto, G. Anderson, 2010, Journal of Pharmacology and Experimental Therapeutics.

Novel terphenyls as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents.

C. Koboldt, K. Seibert, P. Isakson, 1996, Journal of medicinal chemistry.

Probucol attenuates the development of aortic atherosclerosis in cholesterol‐fed rabbits

A Daugherty, G. Schonfeld, A. Daugherty, 1989, British journal of pharmacology.

Isolation of low density lipoprotein from atherosclerotic vascular tissue of Watanabe heritable hyperlipidemic rabbits.

B. Sobel, G. Schonfeld, A. Daugherty, 1988, Arteriosclerosis.

Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitors.

M. Currie, K. Seibert, P. Needleman, 1995, The Journal of clinical investigation.

Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.

B. Levine, J. Masferrer, T. Davis, 2002, Cancer research.

CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain.

J. Masferrer, M. Graneto, G. Anderson, 2009, European journal of pharmacology.

Inhibition of Cyclooxygenase-2 by Celecoxib Reverses Tumor-Induced Wasting

J. Masferrer, T. Davis, B. Zweifel, 2004, Journal of Pharmacology and Experimental Therapeutics.

PAS kinase drives lipogenesis through SREBP-1 maturation.

J. Rutter, B. Zweifel, D. Romero, 2014, Cell reports.

Synergy between Celecoxib and Radiotherapy Results from Inhibition of Cyclooxygenase-2-Derived Prostaglandin E2, a Survival Factor for Tumor and Associated Vasculature

J. Masferrer, T. Davis, M. Pagel, 2004, Cancer Research.

Selective inhibition of Δ-6 desaturase impedes intestinal tumorigenesis

J. Masferrer, M. Mcentee, B. Zweifel, 2002 .

A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.

J. Masferrer, G. Anderson, B. Zweifel, 2008, European journal of pharmacology.

Biochemical, Cellular, and Anti-Inflammatory Properties of a Potent, Selective, Orally Bioavailable Benzamide Inhibitor of Rho Kinase Activity

J. Masferrer, M. B. Norton, M. Payne, 2010, Journal of Pharmacology and Experimental Therapeutics.

Selective inhibition of Delta-6 desaturase impedes intestinal tumorigenesis.

J. Masferrer, M. Mcentee, B. Zweifel, 2002, Cancer letters.

4,5‐Diaryloxazole inhibitors of cyclooxygenase‐2 (COX‐2)

C. Koboldt, K. Seibert, J. Masferrer, 1999, Medicinal research reviews.

Regulation of prostaglandin biosynthesis in vivo by glutathione.

P. Isakson, S. Hauser, B. Zweifel, 1998, American journal of physiology. Regulatory, integrative and comparative physiology.

Regulation of prostaglandin biosynthesis in vivo by glutathione.

M. Anderson, P. Isakson, S. Hauser, 1998, The American journal of physiology.

Leukotrienes, But Not Angiotensin II, Are Involved in the Renal Effects Elicited by the Prolonged Cyclooxygenase-2 Inhibition When Sodium Intake Is Low

J. Masferrer, M. Graneto, B. Zweifel, 2013, Journal of cardiovascular pharmacology.

COX-2 inhibitors and genetic background reduce mammary tumorigenesis in cyclooxygenase-2 transgenic mice.

A. Ristimäki, T. Hla, O. Trifan, 2005, Prostaglandins & other lipid mediators.

Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme.

K. Seibert, P. Needleman, J. Masferrer, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.

J. Masferrer, T. Davis, B. Zweifel, 2002, Cancer research.

Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.

K. Seibert, J. Masferrer, B. Zweifel, 2000, Cancer research.

Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation.

C. Koboldt, J. Masferrer, K. Subbaramaiah, 1999, Cancer research.

4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2.

R. S. Rogers, C. Koboldt, K. Seibert, 2000, Journal of medicinal chemistry.

Synthesis and activity of sulfonamide-substituted 4,5-diaryl thiazoles as selective cyclooxygenase-2 inhibitors.

C. Koboldt, K. Seibert, P. Collins, 1999, Bioorganic & medicinal chemistry letters.

Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor.

J. Gierse, J. Masferrer, J. Carter, 2010, Biochemical pharmacology.

Synthesis and Activity of Sulfonamide‐Substituted 4,5‐Diaryl Thiazoles as Selective Cyclooxygenase‐2 Inhibitors.

C. Koboldt, K. Seibert, P. Collins, 2010 .

Pharmacological analysis of cyclooxygenase-1 in inflammation.

C. Koboldt, K. Seibert, P. Isakson, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.

J. Masferrer, B. Zweifel, K. Leahy, 2002, Cancer research.

Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.

K. Seibert, P. Isakson, J. Masferrer, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Distinct binding and signaling activity of Acthar Gel compared to other melanocortin receptor agonists

B. Zweifel, A. D. Wright, K. Galen, 2020, Journal of receptor and signal transduction research.

In vivo glucocorticoids regulate cyclooxygenase-2 but not cyclooxygenase-1 in peritoneal macrophages.

K. Seibert, S. Reddy, P. Needleman, 1994, The Journal of pharmacology and experimental therapeutics.

The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice.

I. Russo, J. Masferrer, C. Daskalakis, 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

The effects of probucol on the progression of atherosclerosis in mature Watanabe heritable hyperlipidaemic rabbits

A Daugherty, G. Schonfeld, A. Daugherty, 1991, British journal of pharmacology.

Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice.

K. Seibert, P. Needleman, J. Masferrer, 1990, The Journal of clinical investigation.

Valdecoxib: Assessment of Cyclooxygenase-2 Potency and Selectivity

J. Gierse, C. Koboldt, K. Seibert, 2005, Journal of Pharmacology and Experimental Therapeutics.

Specific COX-2 inhibitors: from bench to bedside

C. Koboldt, K. Seibert, P. Isakson, 1998 .

in Human Head and Neck Xenograft Tumors 2 Prostaglandin E Direct Evidence for a Role of Cyclooxygenase 2-derived Updated

J. Masferrer, T. Davis, B. Zweifel, 2002 .

AB0082 REDUCED STEROIDOGENIC ACTIVITY OF REPOSITORY CORTICOTROPIN INJECTION (RCI) INDUCES A DISTINCT CYTOKINE RESPONSE FOLLOWING T CELL ACTIVATION IN VIVO

B. Zweifel, K. Galen, R. Fitch, 2019, Abstracts Accepted for Publication.

Inhibition of cutaneous ultraviolet light B–mediated inflammation and tumor formation with topical celecoxib treatment

D. Kusewitt, T. Oberyszyn, B. Zweifel, 2003, Molecular carcinogenesis.

Epithelial Cells and in a Rat Model of Inflammation Activity and Expression of Cyclooxygenase-2 in Human Oral Inhibitory Effects of Caffeic Acid Phenethyl Ester on the Updated Version

C. Koboldt, J. Masferrer, K. Subbaramaiah, 1999 .

Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B–induced skin cancer

T. Oberyszyn, B. Zweifel, T. Wilgus, 2003, Molecular carcinogenesis.

Enzymologic and pharmacologic profile of loxoprofen sodium and its metabolites.

J. Gierse, M. Sasamata, B. Zweifel, 2005, Biological & pharmaceutical bulletin.

Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.

J. Gierse, C. Koboldt, K. Seibert, 2005, Journal of Pharmacology and Experimental Therapeutics.

Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.

J. Gierse, C. Koboldt, K. Seibert, 2005, The Journal of pharmacology and experimental therapeutics.

Valdecoxib: Assessment of Cyclooxygenase-2 Potency and Selectivity

J. Gierse, C. Koboldt, K. Seibert, 2005, Journal of Pharmacology and Experimental Therapeutics.

Leukotrienes, But Not Angiotensin II, Are Involved in the Renal Effects Elicited by the Prolonged Cyclooxygenase-2 Inhibition When Sodium Intake Is Low

J. Masferrer, M. Graneto, B. Zweifel, 2013, Journal of cardiovascular pharmacology.

THE ROLE OF CYCLOOXYGENASE‐2 IN INFLAMMATION

K. Seibert, P. Isakson, J. Masferrer, 1995, American journal of therapeutics.